Medrx Co. Ltd. reported consolidated earnings results for the nine months ended September 30, 2016. For the nine months, the company reported consolidated net sales of JPY 22 million, operating loss of JPY 1,050 million, ordinary loss of JPY 1,019 million, net loss of JPY 996 million or JPY 125.22 per diluted share, compared to net sales of JPY 35 million, operating loss of JPY 658 million, ordinary loss of JPY 645 million, net loss of JPY 531 million or JPY 79.44 per diluted share, a year ago.

The company provided consolidated earnings guidance for the full year ending December 31, 2016. For the full year, the company is forecasting its net sales of JPY 29 million, operating loss of JPY 1,608 million, ordinary loss of JPY 1,594 million, net loss of JPY 1,572 million or JPY 196.90 per share.